Novavax Net Income From Continuing Ops from 2010 to 2024

NVAX Stock  USD 9.11  0.09  1.00%   
Novavax Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -576.4 M in 2024. During the period from 2010 to 2024, Novavax Net Loss regression line of annual values had significance of  0.01 and arithmetic mean of (339,034,540). View All Fundamentals
 
Net Loss  
First Reported
2000-03-31
Previous Quarter
162.4 M
Current Value
-121.3 M
Quarterly Volatility
122.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0066 or Days Sales Outstanding of 82.31. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
  
Check out the analysis of Novavax Correlation against competitors.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Latest Novavax's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Novavax over the last few years. It is Novavax's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Novavax Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(339,034,540)
Coefficient Of Variation(130.90)
Mean Deviation300,008,853
Median(183,769,000)
Standard Deviation443,807,141
Sample Variance196964.8T
Range1.7B
R-Value(0.64)
Mean Square Error124554.4T
R-Squared0.41
Significance0.01
Slope(63,760,145)
Total Sum of Squares2757506.9T

Novavax Net Income From Continuing Ops History

2024-576.4 M
2023-548.9 M
2022-657.9 M
2021-1.7 B
2020-418.3 M
2019-132.7 M
2018-184.7 M

About Novavax Financial Statements

Novavax investors use historical fundamental indicators, such as Novavax's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-548.9 M-576.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.